Washington Law Review
Volume 91

Number 1

3-1-2016

Buyers in the Baby Market: Toward a Transparent Consumerism
June Carbone
Jody Lyneé Madeira

Follow this and additional works at: https://digitalcommons.law.uw.edu/wlr
Part of the Health Law and Policy Commons

Recommended Citation
June Carbone & Jody L. Madeira, Buyers in the Baby Market: Toward a Transparent Consumerism, 91
Wash. L. Rev. 71 (2016).
Available at: https://digitalcommons.law.uw.edu/wlr/vol91/iss1/3

This Article is brought to you for free and open access by the Law Reviews and Journals at UW Law Digital
Commons. It has been accepted for inclusion in Washington Law Review by an authorized editor of UW Law Digital
Commons. For more information, please contact lawref@uw.edu.

05 - Carbone Madeira.docx (Do Not Delete)

3/23/2016 4:28 PM

BUYERS IN THE BABY MARKET: TOWARD A
TRANSPARENT CONSUMERISM
June Carbone & Jody Lyneé Madeira*
Abstract: This Article assesses the forces on the horizon remaking the fertility industry,
including greater consolidation in the health care industry, the prospects for expanding (or
contracting) insurance coverage, the likely sources of funding for future innovation in the
industry, and the impact of globalization and fertility tourism. It concludes that concentration
in the American market, in contrast with other medical services, may not necessarily raise
prices, and price differentiation may proceed more from fertility tourism than from
competition within a single geographic region. The largest challenge may be linking those
who would fund innovation, whether innovation that produces new high cost products or
innovations making fertility services more accessible and affordable, with the constantly
shifting market niches of a globalized era.

INTRODUCTION .................................................................................. 71
I. BABY MARKETS: THE BUSINESS OF FERTILITY.................. 75
II. REMAKING BABY-MAKING ...................................................... 79
A. The Changing Health Care Landscape ................................... 80
B. Expanding Insurance Coverage .............................................. 86
C. The Future of Innovation........................................................ 93
D. Globalization, Brokers, and Network Creation .................... 100
CONCLUSION .................................................................................... 106

INTRODUCTION
Health care today, taken as a whole, is often characterized by the
increasing consolidation of health care providers, opaque payment
systems in which neither doctors nor patients understand the full price of
medical procedures, and increasing distance between doctors and
patients.
Yet, certain segments of the health care industry such as cosmetic
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surgery, many dental and mental health services, and most of assisted
reproduction, have until recently defied the trends. They did so in large
part because insurance and government subsidies cover a much smaller
portion of these procedures. Instead, these services have usually
occurred in the context of relatively small or solo practices, or university
centers where patients pay for the services they receive with much less
(if any) subsidization or third party involvement, and deal directly with
individual professionals in the process. As a result, market forces
influence supply and demand much more directly than in other parts of
the health care industry, and the health care provider-patient relationship
is a more commercially driven seller-buyer one.
These forces—particularly the absence of wide scale insurance or
government subsidization—have shaped assisted reproduction
technologies (ART) from their inception. Almost every aspect of ART
has been controversial, from the initial use of artificial insemination with
donor sperm (AID), to use of fertility drugs that increase the frequency
of multiple births, to in vitro fertilization (IVF), which permits
conception outside of the human body. The Catholic Church, for
instance, identifies human dignity with conception by a married couple
within a woman’s body, and it therefore opposes IVF—and government
subsidization of IVF—altogether.1 Others have expressed concern about
the health effects of fertility drugs, the hormones used in IVF, the
increased incidence of multiples, and other ART practices.2 The
combination of religious objections to the procedures, and concern that
government inquiries would result in restrictive measures, have blocked
inclusion of ART in national health legislation and funding for research
that would contribute to better understandings of the long term health
risks involved with these procedures.3 Instead, relatively little regulatory
oversight exists and only a small number of states mandate any form of

1. Congregation for the Doctrine of the Faith, Instruction on Respect for Human Life in Its Origin
and on the Dignity of Procreation: Replies to Certain Questions of the Day, VATICAN (Feb. 22,
1987),
http://www.vatican.va/roman_curia/congregations/cfaith/documents/rc_con_cfaith_doc
_19870222_respect-for-human-life_en.html [https://perma.cc/N73Y-YPS9].
2. See, e.g., Michele Goodwin, A View from the Cradle: Tort Law and the Private Regulation of
Assisted Reproduction, 59 EMORY L.J. 1039, 1058–61 (2010) (discussing potential complications
from ART).
3. See June Carbone & Naomi Cahn, Embryo Fundamentalism, 18 WM. & MARY BILL RTS. J.
1015 (2010). The tacit compromise underlying the development of assisted reproduction has been
that “no laws are passed that even tangentially sanction embryo destruction and no laws are passed
that intrude on the profitability of fertility treatments.” Id. at 1015; see also 1032–36. In addition,
“[l]egislative and regulatory oversight of assisted reproduction has been characterized by moral
posturing and regulatory gridlock.” Id. at 1032.
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insurance coverage.4
For most of its existence, therefore, ART practices have taken place in
the context of a different consumer and ethical infrastructure than other
health care services. This means that even where fertility clinics
experience many of the same forces as the rest of the medical profession,
the implications may not be the same. For example, ART practitioners,
like other medical clinics, face pressures to innovate. This innovation
increases returns to scale and take place in the context of global
competition. In the fertility context, consolidation, at least initially, may
offer more rather than less price competition and competition across
jurisdictional lines offers not just opportunities to leverage price
differences but to jurisdiction shop for different regulatory
environments. Competition for providers across state and national lines
may therefore give consumers a wider array of choices.
At the same time, the competition for fertility services involves
selection for particular services as much as, if not more, than selection
for price. The global market for fertility services includes wealthy and
sophisticated patients who may scour the world for a place willing to
provide surrogacy services for older or non-traditional couples. It also
includes those who would like to employ new techniques to select a
child of a desired sex, to avoid the transmission of hereditary diseases, or
to conceive a “savior sibling” capable of providing a bone marrow
transplant to a family member whose life depends on finding a
compatible donor.5 Increased competition and “fertility tourism” may
thus expand the availability of services not just by making them more
affordable, but also by making it easier to evade ethical restrictions that
limit the availability of controversial services.6
4. Insurance Coverage in Your State, RESOLVE, http://www.resolve.org/family-buildingoptions/insurance_coverage/state-coverage.html [https://perma.cc/3TYH-CQNE] (last visited Feb.
23, 2016) (noting that only fifteen states currently offer this coverage).
5. See, e.g., Gender Selection, FERTILITY INSTS., http://www.fertility-docs.com/programs-andservices/gender-selection/select-the-gender-of-your-baby-using-pgd.php?utm_expid=8598529.IPJ9NYcHRJCpZh9q8VY-vg.0&utm_referrer=https%3A%2F%2Fwww.google.com%2F
[https://perma.cc/F8LU-5H46] (last visited Feb. 5, 2016) (providing sex selection as an advertised
service). For a discussion of “savior siblings,” see MALCOLM K. SMITH, SAVIOUR SIBLINGS AND
THE REGULATION OF ASSISTED REPRODUCTIVE TECHNOLOGY: HARM, ETHICS AND LAW 1–2 (2015)
(defining the term and arguing for the use of “saviour children” rather than “saviour sibling” since
the children chosen for such reasons are not necessarily limited to siblings); Susan M. Wolf et al.,
Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines &
Limits, 31 J.L. MED. & ETHICS 327, 330–36, 336 n.5 (2003) (discussing the bioethics issues in
“savior sibling” cases); I. Glenn Cohen, Intentional Diminishment, the Non-Identity Problem, and
Legal Liability, 60 HASTINGS L.J. 347, 364 (2008) (discussing possible feelings of guilt by savior
siblings who refuse to consent to use of their tissue).
6. See Choosing a Medical Tourism Agency to Plan Your Fertility Treatment Abroad, FERTILITY
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Faced with these clinic practices, infertile individuals become
“consumers” as well as patients. Patients may enjoy a choice of clinics
on the east and west coasts of the United States, as well as abroad.7 They
can, and often do, ask exactly what fertility procedures will cost, and can
consider different potential fertility packages in deciding on a course of
action. Still, a larger percentage of the public may pursue less expensive
options in Mexico than those who will price shop within their home
markets in the United States, much less negotiate with individual
providers. Some argue that any form of price consideration reduces one
of life’s most fundamental experiences—the creation of a human life—
to a dollars-and-cents commercial transaction.8 Others express concern
that for-profit clinics press the limits of ethical behavior in their desire to
recruit more patients.9 Yet others hold up fertility clinics as a model of
informed choice: the infertile at least enjoy a choice of clinics, with
transparent prices, that allow the patients to select their preferred course
of treatment.10 Discovering the true cost of cancer surgery is, in contrast,
a much more difficult process.11
This Article will assess the forces on the horizon remaking the
fertility industry. In Part I, the Article discusses the differences between
health care generally and ART services and the forces that produce these
differences. In Part II, the Article identifies looming events remaking the
nature of fertility services. These forces include the impact on ART
services of greater consolidation in the health care industry, the
prospects for expanding (or contracting) insurance coverage, the likely
sources of funding for future innovation in the industry, and the impact
of globalization and fertility tourism. The Article conducts this inquiry
TREATMENT ABROAD, http://fertility.treatmentabroad.com/agencies/choosing-a-medical-tourismagency [https://perma.cc/CE8Y-93H3] (last visited Feb. 5, 2016).
7. See infra notes 54–55 (describing clinic efforts to increase geographic reach within the United
States); infra notes 153–70 and accompanying text (describing growth of fertility tourism across
international lines); DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND POLITICS
DRIVE THE COMMERCE OF CONCEPTION 54 tbl.2-1 (2006) (describing location of largest clinics,
which tend to be concentrated in the East Coast, and major U.S. cities).
8. ANTHONY OAKLEY DYSON, THE ETHICS OF IVF 35 (1995) (stating that “IVF involves the
commodification, commercialization and exploitation of persons and processes”).
9. See, e.g., Goodwin, supra note 2, at 1056 (suggesting that “aggressive fertility claims distort
reproductive realities and misinform patients; ART’s failure rate is estimated to be 70%”).
10. See Jody Lyneé Madeira, Conceiving of Products and the Products of Conception: Reflections
on Commodification, Consumption, ART, and Abortion, 43 J.L. MED. & ETHICS 294, 299–300
(2015) (summarizing the debate).
11. See, e.g., STEVEN BRILL, AMERICA’S BITTER PILL: MONEY, POLITICS, BACKROOM DEALS,
AND THE FIGHT TO FIX OUR BROKEN HEALTHCARE SYSTEM (2015) (documenting opaque billing
practices in health care).
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by examining the changing business model of the industry and
recounting interviews with providers about the potential consequences of
that change.
In Part III, the Article concludes that future developments will likely
remake the industry in fundamental ways. The United States, long a
pioneer in fertility clinics, has taken a largely free market approach to
innovation that stands in contrast with the development of other medical
advances, which are far more likely to be the product of either
substantial public funding or extensive government oversight.
Innovation in the future is increasingly likely to occur either through
private funding or abroad. In either event, the relationship between
providers, patients, and regulatory authorities is likely to be more
attenuated. Accordingly, the Article concludes that concentration in the
American market, in contrast with other medical services, may not
necessarily raise prices, and price differentiation may proceed more from
fertility tourism than from competition within a single geographic
region. The largest challenge may be linking those who would fund
innovation, whether innovation that produces new high cost products or
innovations making fertility services more accessible and affordable,
with constantly shifting market niches of a globalized era.
I.

BABY MARKETS: THE BUSINESS OF FERTILITY

Health care, of course, has long been a business. In some eras, it has
been a service that could be separated into for-profit and not-for-profit
sectors.12 That changed with the development of third-party payment
systems.13 In 1940, ten percent of Americans had health insurance.14 By
1957, that number increased to seventy-two percent, prompted primarily
by the growth in employer-provided health insurance.15 The expansion
of Medicare and Medicaid extended health care coverage to the elderly
and the poor, who did not have or could not get other health care
benefits.16 By 2013, the percentage of the American public not covered
by any health insurance had dropped to fourteen percent.17 As a result,
12. See Terry L. Corbett, Healthcare Corporate Structure and the ACA: A Need for Mission
Primacy Through a New Organizational Paradigm?, 12 IND. HEALTH L. REV. 103, 110 (2015)
(discussing how non-profit hospitals once gave doctors greater freedom from market pressures).
13. Id. at 121.
14. Eleanor D. Kinney, For Profit Enterprise in Health Care: Can It Contribute to Health
Reform?, 36 AM. J.L. & MED. 405, 409 (2010).
15. Id.
16. Id. at 409, 411–12.
17. JESSICA C. SMITH & CARLA MEDALIA, U.S. CENSUS BUREAU, HEALTH INSURANCE
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even medical providers with a mandate to cover underserved populations
do not provide services without charge. Instead, they receive substantial
revenues from third-party payers.18 Further, with third-party payers such
as private insurance companies or state-run Medicare and Medicaid
programs, the doctor may not necessarily be aware of the true cost of the
treatment or the relationship between those costs and what patients pay
directly.19
The development of fertility treatments, in contrast, has taken place in
relatively smaller clinics that rely to a much greater degree on customers
who pay out-of-pocket.20 The portion of the population most likely to be
concerned about fertility issues is also the least likely to have health
insurance; those between the ages of eighteen and thirty-five—the peak
childbearing years—are less likely than younger or older people to have
health care coverage.21 Only fifteen states mandate any fertility
coverage, and their mandates are neither comprehensive nor uniform.22
COVERAGE
IN
THE
UNITED
STATES:
2013,
at
4
fig.4
(2014),
https://www.census.gov/content/dam/Census/library/publications/2014/demo/p60-250.pdf
[https://perma.cc/G4X7-WPG9].
18. See, e.g., Erin C. Fuse Brown, Irrational Hospital Pricing, 14 HOUS. J. HEALTH L. & POL’Y
11, 37 (2014) (explaining charity care hospital billing practices).
19. Id. at 16, 35 n.127 (noting that hospital prices remain almost completely opaque, variable
even with the same hospital and unintelligible and involve both physician and hospital components).
20. See Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers, Indelible
Harms, 23 BERKELEY J. GENDER L. & JUST. 18, 37 (2008) (observing that insurance mandates have
relatively little effect on fertility treatment usage because those with insurance coverage are the
patients most likely to be able to afford fertility treatments on their own); Marianne Bitler & Lucie
Schmidt, Health Disparities and Infertility: Impacts of State-Level Insurance Mandates, 85
FERTILITY & STERILITY 858, 864 (2006). But see SPAR, supra note 7, at 33 (observing that there are
still barriers to entry, given the lengthy training necessary to be able to do IVF, and returns to scale).
21. SMITH & MEDALIA, supra note 17, at 6 fig.4. Racial disparities are also substantial, with the
highest utilization among older, educated Caucasian women with income greater than 300 percent
above the poverty level. Low-income women with under twelve years of education were the least
likely to access infertility services. See Eve C. Feinberg et al., Comparison of Assisted Reproductive
Technology Utilization and Outcomes Between Caucasian and African American Patients in an
Equal-Access-to-Care Setting, 85 FERTILITY & STERILITY 888, 889 (2006). Yet, lower income and
minority women experience higher rates of involuntary infertility. Daar, supra note 20, at 39
(“Hispanic women, non-Hispanic black women, and other women of color are significantly more
likely to be infertile than white women.”); see Kimberly M. Mutcherson, Transformative
Reproduction, 16 J. GENDER RACE & JUST. 187, 222 (2013) (“[A] disproportionate number of
infertile women in this country are Black.”).
22. Seema Mohapatra, Fertility Preservation for Medical Reasons and Reproductive Justice, 30
HARV. J. RACIAL & ETHNIC JUST. 193, 206 (2014); see also Tara Siegel Bernard, Insurance
Coverage for Fertility Treatments Varies Widely, N.Y. TIMES (July 25, 2014),
http://www.nytimes.com/2014/07/26/your-money/health-insurance/insurance-coverage-for-fertilitytreatments-varies-widely.html [https://perma.cc/Q72F-QLRL] (noting that of the states that mandate
coverage, only eight—Arkansas, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, New
Jersey and Rhode Island—require some level of coverage for IVF).
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In the states that do not mandate coverage, insurance companies
typically do not cover such treatments, thus utilization of fertility
services falls.23 Public programs such as Medicaid similarly treat fertility
issues as elective and uncovered, and private charities do not place much
emphasis on access to services such as IVF.24 Deborah Spar estimates
that only a little more than one-third of the infertile seek fertility
treatments.25
As a result, fertility treatments, much like cosmetic surgery or
dentistry, traditionally took place in fragmented practices dependent on
out-of-pocket patient payments.26 This is changing, however, as clinics
consolidate to take advantage of economies of scale. These clinics treat
patients who are socioeconomically advantaged27 and, with fewer thirdparty imposed requirements, they may be quite profitable.28 Still, they
depend on the patients’ ability and willingness to pay.
The United States provides relatively little regulation of fertility
treatments.29 Federally mandated reporting requirements, which include
23. See Melinda B. Henne & M. Kate Bundorf, Insurance Mandates and Trends in Infertility
Treatments, 89 FERTILITY & STERILITY 66 (2008) (noting that comprehensive insurance mandates
are associated with greater utilization of ART and lower rates of births per cycle and multiple births
per ART birth); John A. Robertson, Commerce and Regulation in the Assisted Reproduction
Industry, 85 TEX. L. REV. 665, 674 (2007) (reviewing SPAR, supra note 7, and discussing the
limited availability of insurance coverage for assisted reproduction).
24. Mohapatra, supra note 22, at 223.
25. SPAR, supra note 7, at 32.
26. See, e.g., Kimberly D. Krawiec, Altruism and Intermediation in the Market for Babies, 66
WASH. & LEE L. REV. 203, 213–14 (2009) (“[P]rofits are undeniably a—if not the—motivating
factor in the industry as well. Although many fertility centers are affiliated with nonprofit hospitals
or academic institutions, the fertility center itself is often a professionally managed, for-profit,
private corporation.” (emphasis in original)); HARRIS WILLIAMS & CO., FERTILITY MARKET
OVERVIEW (2015) [hereinafter FERTILITY MARKET OVERVIEW], http://www.harriswilliams.com/
sites/default/files/content/fertility_industry_overview_-_2015.05.19_v10.pdf
[https://perma.cc/WA9W-2FGN] (commenting on highly fragmented nature of the U.S. market).
27. Patients with higher incomes tend not just to be better able to pay for fertility treatments on
their own; they are also more likely to have health insurance, and to have insurance that covers
fertility treatments. On health insurance coverage, see SMITH & MEDALIA, supra note 17, at 9 tbl.4.
28. See, e.g., Debora Spar & Anna M. Harrington, Building a Better Baby Business, 10 MINN. J.L.
SCI. & TECH. 41, 49 (2009) (“ART has become a big business in the United States precisely because
it costs so much.”). Spar and Harrington estimate the cost per live birth (using a fifty-one percent
success rate) at between $29,411 and $49,020. Id. at 50.
29. Judith Daar emphasizes that this perception of American practices comes from the lack of a
“top-down” system in the United States, but that the notion that American fertility clinics are the
wild west of medicine is an “urban myth.” Judith Daar, Federalizing Embryo Transfers: Taming the
Wild West of Reproductive Medicine?, 23 COLUM. J. GENDER & L. 257, 257, 266 (2012). She
emphasizes instead that American reproductive practice, like all others areas of medicine, “is subject
to quality control through a variety of mechanisms, most notably licensure of physicians by statebased medical boards, application of practice standards established by professional societies, and
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reports of success rates, constitute the most direct regulation.30 Perhaps
as importantly, the lack of federal research support also influences
industry practices.31 Even when there is no direct public oversight of
medical practices, federal grants often prompt medical innovations
through research funds typically conditioned on agreement to observe
ethical practices prescribed by professional groups or committees.32
Congress, however, has restricted research on embryos since the 1970s,
starting almost immediately after the legalization of abortion. These
efforts culminated in the “Dickey Amendment,” which has been attached
to every Health and Human Services appropriations bill since 1996.33
The amendment forbids federal funding for “research in which a human
embryo or embryos are destroyed, discarded, or knowingly subjected to
risk of injury or death.”34 Fertility clinics therefore rely either on private
research funding, with relatively few restrictions compared to federal
grants,35 or their patients’ willingness to undergo certain untested IVF

private tort litigation.” Id. at 262. These physician-based regulatory systems, however, tend to be
voluntary rather than mandatory, suggesting professional guidelines without necessarily prohibiting
alternative practices. In addition, enforcement, if it occurs at all, typically occurs after harm has
occurred. In the case of “Octomom” Nadya Suleman, for example, her doctor violated professional
guidelines in implanting a large number of embryos, and ultimately lost his medical license because
of it. Id. at 313–14. Yet, no regulation controls the acceptable number of embryos that can be
implanted at one time, and the after-the-fact-actions taken against the doctor involved almost
certainly reflect the publicity the case generated, and the utterly irresponsible nature of the doctor’s
actions. Id. at 314 (noting that the doctor’s appeal was rejected because of the “serious breach of the
standard of care”).
30. Id. at 267–68 (discussing comprehensive reporting requirements); see also Fertility Clinic
Success Rate and Certification Act, 42 U.S.C. § 263(a)(l)–(7) (2012). Federal regulations also cover
laboratory testing. See Clinical Laboratory Improvement Act of 1988, 42 U.S.C. § 263(a); 21 C.F.R.
§§ 1271.55, 1271.80 (2016) (implementing regulations).
31. See Carbone & Cahn, supra note 3, at 1052. In contrast, the federal government had once
funded the vast majority of biomedical research. See June Carbone, Toward a More Communitarian
Future? Fukuyama as the Fundamentalist Secular Humanist, 101 MICH. L. REV. 1906, 1923 (2003).
32. See Note, Guiding Regulatory Reform in Reproduction and Genetics, 120 HARV. L. REV. 574,
579 (2006).
33. Carbone & Cahn, supra note 3, at 1033–34.
34. Balanced Budget Downpayment Act, Pub. L. No. 104-99, § 128, 110 Stat. 26, 128 (1996).
The 2005 version of the amendment provided:
None of the funds made available in this Act may be used for . . . research in which a human
embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death
greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b) and section
498(b) of the Public Health Service Act (42 U.S.C. 289g(b)).
Department of Health and Human Services Appropriations Act, 2006, Pub. L. No. 109-149, § 509,
119 Stat. 2833, 2880 (2005).
35. Note, supra note 32, at 586–87 (observing that IVF clinics had little difficulty attracting
private research funds, and in this context, “caution was not a foremost concern, and few external
forces existed to slow the work of the clinic”).
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procedures such as using genetic material from three individuals without
clinical trials beforehand.36
Despite the lack of public research support, the combination of private
support, lack of restrictions, and paying patients has allowed the United
States to develop a large, profitable fertility industry—one whose
potential impact is likely to grow.37
II.

REMAKING BABY-MAKING

Newsweek ran a piece a number of years ago, before the end of
the cold war, that recited a little ditty attempting to explain
differences in national political cultures. It went something like
this: in the United States, everything is allowed unless it is
specifically prohibited; in East Germany, everything is
prohibited unless it is specifically allowed; in the Soviet Union,
everything is prohibited especially if it is allowed; and in Italy,
everything is allowed especially if it is prohibited. While casual
and perhaps too cute, this ditty nonetheless captures some
fundamental approaches to governance. The NBAC [President
Clinton’s National Bioethics Advisory Commission] took this
advice to heart.38
A decade and a half ago, Alto Charo’s ditty summarized the state of
the fertility business. National cultures—public and private—determined
the approaches to fertility treatments, and in the United States, public
bodies mostly looked the other way, allowing private entities to oversee
the development of the industry largely on their own. To be sure, the
occasional front page news story, from Baby M39 to Octomom,40 focused
the spotlight on fertility practices and led to narrowly focused reforms,

36. See Carbone, supra note 31, at 1920–21 (attributing lack of animal testing to lack of research
funding); infra Section II.C (describing the cytoplasmic research that occurred at St. Barnabas in
1996). The Food and Drug Administration, however, has since asserted jurisdiction over such
procedures, with the result that such direct testing on patients has become more likely to take place
abroad. See infra note 104 and accompanying text.
37. See generally SPAR, supra note 7 (arguing that it is necessary to acknowledge the commercial
implications of fertility treatment and its market dynamics).
38. R. Alta Charo, Cloning: Ethics and Public Policy, 27 HOFSTRA L. REV. 503, 508 (1999).
39. See In re Baby M., 537 A.2d 1227 (N.J. 1988) (invalidating surrogate parenting arrangements
for violating state law, enacted long before the practice of surrogacy was known in the state,
prohibiting the payment of money in connection with adoption).
40. See, e.g., Naomi R. Cahn & Jennifer M. Collins, Eight Is Enough, 103 NW. U. L. REV.
COLLOQUY 501, 501 (2009) (critiquing IVF practices that led to the birth of octuplets and proposing
limits on the number of embryos to be implanted at any one time).
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but no comprehensive oversight of the industry emerged.41 Nonetheless,
new factors may prompt reconsideration; this Part examines these factors
in turn. Section II.A considers the changing nature of health care more
generally as new technologies and regulations bring increasing returns to
scale. Section II.B then examines how increased demand for fertility
services and the growing evidence that links reproductive efforts and
children’s health to adult genetic predispositions is increasing the
demand for insurance coverage. Section II.C considers the cumulative
effect of narrowly focused regulations on the climate for innovation, as
the combination of federal limits and state restrictions affect
developments on the horizon. Finally, Section II.D. addresses how the
globalization of the supply of fertility services and customer demand
make the relevant markets for fertility services increasingly international
in scope.
A.

The Changing Health Care Landscape

Consolidation increasingly characterizes the health care landscape,
with individual physicians selling practices to larger entities,42 hospital
associations becoming larger, and insurance companies merging. 43 These
trends began in the 1990s,44 accelerated with a shift in Medicare
reimbursement formulas,45 and increased further after adoption of the
Affordable Care Act (ACA) in 2009.46 Some of the reasons for these
41. Indeed, as Charo notes, some bodies such as the NBAC, which were set up to consider
oversight, did not enact reforms. Charo, supra note 38. In Georgia, which took up legislation
designed to curb fertility practices, the only result was state authorization of embryo adoption
procedures, but not limitations on the fertility industry. Cahn & Collins, supra note 40, at 508; see
also Carbone & Cahn, supra note 3, at 1041–43 (recounting Georgia’s efforts to place limits on
embryo implantation after 100,000 people contacted the state legislature opposing the measure).
42. See Lucia DiVenere, The Affordable Care Act and the Drive for Electronic Health Records:
Are Small Practices Being Squeezed?, 25 PRAC. MGMT. 36, 36 (2013),
http://www.jfponline.com/fileadmin/qhi/obg/pdfs/0713_PDFs/0713_OBG_DiVenere.pdf
[https://perma.cc/RQX2-2GLR] (“In 2000, 57% of all physicians were in independent practice; by
the end of 2013, only 36% of physicians are projected to remain independent.”).
43. See, e.g., Thomas F. Cotter, Patents, Antitrust, and the High Cost of Health Care, ANTITRUST
SOURCE, Apr. 2014, at 1, 5 (“[T]he market for health care related services has become remarkably
more concentrated over the past two decades.”); Brandon Gould, How the Countervailing Power of
Insurers Can Resolve the Tradeoff Between Market Power and Health Care Integration in
Accountable Care Organizations, 22 GEO. MASON L. REV. 159, 178 (2014).
44. Cotter, supra note 43, at 5.
45. Gould, supra note 43, at 167 (noting the origination of some of the pressures for consolidation
with creation of accountable care organizations, first implemented as part of Medicare
reimbursement reforms).
46. See 5 Forces Driving Hospital Consolidation, STRATASAN (July 10, 2013),
http://stratasan.com/5-forces-driving-hospital-consolidation/
[https://perma.cc/7BTA-ZNEA]
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trends will have little if any impact on reproductive care. For example,
the change in Medicare reimbursement formulas to emphasize outcomeoriented health care is likely to have little effect on fertility services.47
Nonetheless, other industry trends may affect fertility clinics as well.
First, even if everything else were to stay the same, one of the factors
driving consolidation is the increased costs associated with the switch to
electronic records. Industry observers note that “the healthcare sector’s
reliance on increasingly sophisticated electronic medical records and
other health information technologies to reduce costs and enhance
quality, safety, and efficiency are foundational to healthcare reform.”48
Yet, moving from a paper-based to an electronic system is expensive.
The average cost of an electronic medical records system is $50,000 per
physician,49 and implementing such a system requires training,
maintenance, and compliance with various privacy laws and regulatory
requirements that generate additional costs.50 The need to acquire and
maintain these systems creates returns to scale that encourage larger
practices or cost-sharing administrative groups. In itself, the switch to
electronic records may be a problem of transition; over time, it may
interact with other changes to encourage consolidation of a fragmented
industry.
Fertility clinics face further pressures to consolidate because of the
returns to scale within the industry. Deborah Spar reports that smaller,
private clinics have faced increased pressure to join networks such as
IntegraMed, which provides member clinics with “management advice,
pharmaceutical products, and in house-financing.”51 These networks may
be better able to negotiate with drug companies for volume discounts,52
they can ease the problems associated with financing new equipment and
lab maintenance in a rapidly changing field, and they offer advantages in

(showing an increase in mergers post-2009).
47. Gould, supra note 43, at 178 (“Reliance on Medicare data may also be inappropriate for
services infrequently provided to Medicare beneficiaries, such as pediatric and obstetric care.”).
48. Brian Kerby, The Top Five Drivers of Healthcare Consolidation in 2015, CROW HORWATH
(Apr. 21, 2015), http://www.crowehorwath.com/insights/healthcare-connection/top-five-drivers-hcconsolidation-2015.aspx [https://perma.cc/AS5K-CEQE].
49. Paul R. Brezina et al., How Obamacare Will Impact Reproductive Health, 31 SEMINARS
REPROD. MED. 189, 194 (2013).
50. Id.
51. SPAR, supra note 7, at 51.
52. An industry analyst reports that the U.S. fertility services market of about $3 to $4 billion
consists of $1.7 to $2.5 billion in fertility services and approximately $1.5 billion for fertility
medications. See FERTILITY MARKET OVERVIEW, supra note 26, at 1.
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advertising and new patient acquisition.53 As a result, fertility clinics,
like the rest of the health care field, are experiencing increasing
consolidation.54 The result does not just increase clinic size; it also
expands clinic geographic reach.55
Interviews with fertility industry professionals underscore the
accuracy of Spar’s assertions, though the doctors’ impressions (and
business knowledge and savvy) vary considerably. One physician
remarked:
[W]hen you talk to physicians in our field . . . there’s a strong
sense that consolidation is occurring, and the forces that are
driving us . . . [are] to be able to have electronic medical records,
being able to have the embryology resources and technology,
and all the other back office, IT and marketing and all the types
of things you need today to . . . compete. It’s hard to do as a solo
practice.56
An executive with a for-profit fertility clinic management corporation
stressed the importance of “efficiencies of scale”: “[g]roup purchasing is
a big one. The cost of equipment. If that’s done through group
purchasing arrangement[s], they can get really good discounts through a
larger organization. . . . Or also, the financial advantages if they want to
expand—it’s very expensive to build out a practice.”57 Finally,
consolidation may improve research, which may be particularly
important for university centers: in a large group, “[b]ecause the EMR
[Electronic Medical Records] is linked to all these practices, they have a
massive database. So they can actually provide fantastic data for any
form of research that’s being done within the organization. So they get
recognition—academic recognition—as much as clinical recognition.”58
Doctors also perceive that consolidation may be a response to tough

53. SPAR, supra note 7, at 51 (describing a doctor who joined his practice to IntegraMed reporting
that it allowed him to keep his practice open “52 weeks a year, fully staffed all the time, offering
even the most exotic reproductive technologies”).
54. FERTILITY MARKET OVERVIEW, supra note 26, at 9 (noting that small industry players want
to broaden their access to patients and that referral networks and platform providers like Integra
seek affiliation with additional practices to spur growth, realize synergies, and increase geographic
presence).
55. Id.
56. Telephone Interview by Jody Lyneé Madeira with Anonymous Physician Two (Aug. 15,
2015) (on file with author) [hereinafter Interview with Physician Two].
57. Telephone Interview by Jody Lyneé Madeira with Anonymous Fertility Clinic Management
Corporation Executive (Aug. 29, 2015) (on file with author) [hereinafter Interview with
Management Corporation Executive].
58. Id.
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market conditions. An executive in a for-profit fertility clinic
management corporation described these changing dynamics: “I think
it’s very difficult for a single physician, or even [a] two physician
practice, to survive because of the changing demographic. A lot of the
population is getting older. . . . It’s very difficult for them in the current
[climate], especially with insurance issues.”59 An official with a fertilityrelated nonprofit explained the logic behind consolidation:
[Y]ou have a lot of people who can’t access it, so the field isn’t
growing. And so you’ve got . . . to figure out how you’re gonna
keep sustaining. So a lot of times, that’s consolidation. That’s
[saying], “Look the guy across the stress is struggling too, or
maybe not so much struggling, but we’re all sort of status quo;
maybe if we join forces, we’ll be more efficient, we’ll capture
more of the . . . patient population, and we’ll be in a position to
continue as an entity, to grow and improve.”60
There is much speculation that the ACA, in particular, will prompt
further consolidation.61 As an executive at a for-profit fertility
pharmaceutical corporation stated:
[I]t’s kind of analogous on some level to what we’ve seen in the
hospitals in the [1980s] where . . . the small regional hospitals
were kind of consolidating to form . . . bigger, more
geographically dispersed conglomerates. . . . [Everyone’s going
to] speculate that okay, we have the Affordable Care Act
looming in 2016, most states won’t be able to afford to include
fertility in their essential health benefits package. And that’s
gonna . . . repeal, or lessen the effects of these mandates
and . . . the whole market’s going to drop back from a heavily
managed market to probably more of a cash market, which will
shrink the market significantly. . . . These practices are realizing
that to be competitive in this space, and potentially be
competitive in the next five to ten years . . . that they’re going to
have to figure out how to do this more effectively, costeffectively. And consolidation seems to be the approach. . . . A
lot of the practices that are doing this are already the largest
59. Id.
60. Telephone Interview by Jody Lyneé Madeira with Anonymous Non-Profit Official (Aug. 28,
2015) (on file with author) [hereinafter Interview with Non-Profit Official].
61. The ACA requires the U.S. Department of Health and Human Services (HHS) to establish a
minimum level of health benefits that must be offered by certain health plans that are participating
in the individual and small group health insurance markets. HHS could chose to include fertility care
as a benefit within the maternity care category, but it has not yet made a decision on the issue. See
Daar, supra note 29, at 322.
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practices in their region. And . . . now they’re just moving out
and gobbling up their local competition, . . . realizing they just
can’t compete with the economies of scale working against
them.62
The trend toward consolidation in the fertility industry may be unique
in some respects. This physician felt that consolidation patterns in
fertility medicine were different than in other fields of medical practice:
I don’t think we feel the pressures as much as in other
fields. . . . I know there are hospitals gobbling up practices,
particularly primary care-type practices, [and that] hasn’t
touched us yet. . . . [M]ost IVF centers don’t want to be
restricted, . . . and beholden to a hospital system, so the few that
are still in them . . . often look at ways of getting out of there.63
A top official in a nonprofit fertility organization noted that, not only
is there a trend toward consolidation, but practices in one state are
beginning to expand outside their current regions and other clinics in the
same region may merge:
I think what we’ve seen . . . in the last couple of years are larger
clinics—so they might be top ten or top fifteen in the U.S. in
terms of number of IVF cycles—that are expanding outside their
original states, into other states. So you see this with clinics such
as Shady Grove Fertility going to Pennsylvania. You’ll see
clinics like Boston IVF opening offices in New York, like
Albany, and . . . Colorado Center for Reproductive Medicine, or
CCRM, . . . opening an office in Houston, Texas. . . . [T]he other
thing is . . . clinics in the same marketplaces that are either
merging [or] consolidating. . . . [Y]ou saw the announcement
that RMA of New Jersey, which is one of the largest clinics in
the country, is forming a “partnership” with . . . Shady Grove
Fertility.64
Some may have concerns that consolidation could negatively impact
patients’ care experience. One physician opined, “customer experience is
a number one issue and they don’t want to feel like cattle or like [a]
number, like they usually feel when they’re in these big centers where
they have . . . three, four thousand cycles a year.”65 Another physician
62. Telephone Interview by Jody Lyneé Madeira with Anonymous Pharmaceutical Corporation
Executive (Sept. 11, 2015) (on file with author) [hereinafter Interview with Pharmaceutical
Corporation Executive].
63. Interview with Physician Two, supra note 56.
64. Interview with Non-Profit Official, supra note 60.
65. Telephone Interview by Jody Lyneé Madeira with Anonymous Physician One (Aug. 13,
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stressed, “I wouldn’t want to imply that the choice is between a small,
wonderful practice, or a big, . . . unfeeling conglomerate.”66 That
physician did believe, however, that larger practices could focus more
intensely on creating a personalized patient experience:
I think we’re very big. . . . Every patient at our practice has one
physician and one nurse and a home office[,] and I think we’ve
worked really hard to avoid that perception, or that
experience. . . . And we give patient surveys quarterly, and we
[give] our staff a bonus for patient satisfaction. All these things
are critical to us. So I think a smart, big consolidated group will
recognize how critical patient care and patient experience is, and
will probably do better. . . . I think that big practices have the
ability to look at the data, and the desire to[,] and the resources
to ensure best practices, . . . high quality technology, and the
embryology lab in particular, so I think there’s an advantage.67
Interestingly, this physician also objected to the use of “conglomerate”
versus “consolidation”: “[conglomerate] has such negative
implications. . . . [I]t implies impersonal, profit-driven, without any
thought for quality of patient care.”68 The official in a fertility-related
nonprofit agreed: “however they set up their teams, [the large practices
have] been able to do it in such a way that patients still feel an incredible
connection to that practice.”69
Finally, consolidation can promote best practices. According to
Physician
One,
“we
physicians, . . . we’re
not
good
collaborators, . . . especially the [baby] boom generation.”70 If this is
true, consolidation helps to break down barriers to collaboration:
IntegraMed, for instance, has an annual conference in which
[best practices] are shared . . . and they’re looking at outcomes
and . . . encouraging practices to share best practices, and when
you’re part of the network, you’re much more transparent with
each other, without the posturing that you would have with a
typical large ASRM meeting.71
The official in a fertility-related nonprofit organization stressed that
consolidation enables the latest technologies to spread from practice to
2015) (on file with author) [hereinafter Interview with Physician One].
66. Interview with Physician Two, supra note 56.
67. Id.
68. Id.
69. Interview with Non-Profit Official, supra note 60.
70. Interview with Physician One, supra note 65.
71. Interview with Physician Two, supra note 56.
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practice:
RMA of New Jersey . . . they’ve really developed this
chromosomal screening . . . . that technology is [now being
used] in many practices, so it’s sort of like leveling the playing
field . . . [T]hat’s a technology that is still proprietary to RMA of
New Jersey, but they’re . . . partnering with other clinics to offer
that.72
The official also noted that larger firms tended to “have more ability
to offer financing programs” and that biotech firms developing new
technologies were “going to the large practices to do their testing, and
the larger practices seem to be more open to being early adopters.”73
While these doctors differ in their attribution of cause and effect, and
they differ significantly in their knowledge of and ability to assess
business trends, they tend to agree that consolidation is an increasing
characteristic of the fertility industry, and that the consolidation trend is
likely to continue. Deborah Spar concludes that the most successful
clinics “are either very high volume or very high tech,” and the need to
compete in such an arena is squeezing the profit margins of the “smaller,
less sophisticated, less commercial” clinics, increasing the pressure to
merge.74 Doctors’ sense that continuing market pressure produces greater
consolidation is almost certainly accurate.
B.

Expanding Insurance Coverage

A potentially sweeping effect on the structure of the fertility market is
the possibility of greater insurance coverage. Spar describes insurance
coverage as a double-edged sword for the fertility industry:
On the one hand, when insurers cover infertility as a medical
illness, they nearly guarantee a greater demand for fertility
treatments: people who previously couldn’t afford treatment
suddenly enter the market, and people who bought minimal
services now buy more. Thus, political demands in this industry
can easily translate into expanded commercial demand. On the
other hand, though, insurance coverage comes at a cost, forcing
providers to charge only what the insurers will pay.
Accordingly, insurance—and even the threat of insurance—acts
to cap prices in the industry and put an even greater premium on

72. Interview with Non-Profit Official, supra note 60.
73. Id.
74. SPAR, supra note 7, at 58.
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volume.75
Spar’s analysis follows from the relative lack of price competition for
IVF, which creates greater incentives for clinics to try to enter the upper
end of the market rather than to expand volume through lower prices.76
Ironically, while fertility clinic pricing is more transparent than pricing
in forms of medicine covered by third-party payers, clinic prices tend to
be relatively uniform across clinics, and customers tend not to
comparison shop on the basis of price, at least within a given regional
market.77 Insurance companies, in contrast, are repeat players with more
information and greater market power, giving them greater ability than
consumers to negotiate lower prices.78
Doctors believe that the fact that most patients pay all or most of their
IVF treatment costs already has made IVF more cost-effective than other
forms of medical care that are subsidized by insurance. Physician Two
observed the following:
[W]hen a high percentage of patients pay out-of-pocket, you
have to really focus on being transparent and competitive about
pricing. And that, I think, is good for patients in this field. I
think that fertility treatment is expensive, but actually if you
compare it to “What is my IVF cycle cost versus an arthroscopy
of the knee?” I think IVF is much more technically challenging
and cost-effective and complex, and the time spent by people is
much greater, but yet the arthroscopy probably gets twice as
much, because of hospitals and surgery centers and the
equipment manufacturers and everything else. . . . [F]ertility
treatment’s price rises ha[ve] been less than medicine by a long,
long way because of the transparency and the fact that patients
are self-paying.79
Yet, as Spar indicates, while the lack of third-party payment has
restricted the size of the market, it has increased emphasis on high profit
procedures rather than lower cost, higher volume approaches.80
Expanded insurance coverage would change this dynamic, and could
thus have a major impact on future industry development. So, however,
could cutbacks in existing insurance coverage, which would have the
75. Id. at 34 (emphasis in original).
76. Id. at 65.
77. Id. at 59 (listing prices).
78. Id. at 58.
79. Interview with Physician Two, supra note 56.
80. Spar describes clinics as competing to serve wealthy clients, with relatively high value, high
profit services, rather than expanding volume. SPAR, supra note 7, at 34.
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most effect in places like Massachusetts that now mandate broader
insurance coverage.81
Recent interviews with reproductive industry professionals suggest
that the ACA provides no incentives for retaining insurance mandates
compelling fertility services coverage, and speak to the dramatic changes
in store should those mandates terminate in 2016. As one physician
remarked:
[T]here has to be a basic package, a basic basket of services that
are offered. . . . So IVF would not be in a basic basket of
services. So that may be the basis by which the state would then
say, “Well hang on, if the basic medical package doesn’t include
IVF, then it shouldn’t be a state mandate for IVF” . . . . I think
the field . . . is anxious about . . . what the implications will
be. . . . Nobody really knows what it means. . . . There’s a big
school of thought that the mandates will disappear . . . I know
we didn’t sign an expensive lease on a new space because we
were worried . . . .82
Insurance coverage need not extend to every aspect of IVF or other
fertility treatments to have an effect. Current fertility-related medical
coverage has three components: (1) diagnosis and treatment of
underlying disorders that contribute to infertility such as endometriosis
and surgery to correct it; (2) procedures designed to produce a pregnancy
such as in IVF; and (3) medical care for pregnant women, and care of the
resulting children.83 Insurance routinely covers costs associated with the
first and third, but not treatments such as IVF aimed at fertility per se.84
In addition, some prospective patients who would like access to IVF may
have no known disorders,85 and with increasing numbers of same-sex
couples having children with third-party participants, some of the
demand for assisted reproduction does not involve medical infertility at

81. See MASS. GEN. LAWS ANN. ch. 175, §§ 1–227 (West, Westlaw through 2015 1st Annual
Sess.); 211 MASS. CODE REGS. 37 (2016).
82. Interview with Physician Two, supra note 56.
83. See, e.g., Michael H. Shapiro, What Should Insurance Insure in the PPACA Age? On Paying
for Other People’s Reproductive Decisions and Ambitions, 33 WHITTIER L. REV. 27, 29 (2011)
(noting that health care insurance is certainly expected to cover medical disorders and pregnancyrelated illnesses and expenses).
84. Insurers have argued that, while improper function of reproductive organs may be an illness,
infertility is not. See Noah Baron & Jennifer Bazzell, Assisted Reproductive Technologies, 15 GEO.
J. GENDER & L. 57, 78 (2014).
85. FERTILITY MARKET OVERVIEW, supra note 26, at 2, put the percentage of “unexplained”
infertility at twelve percent.
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all.86
Industry professionals are well aware of the problems resulting from a
lack of insurance coverage for infertility; as one physician stated, “from
[one] hundred patients that require in vitro fertilization as a
treatment . . . only ten to twenty are getting it in the States.”87 Another
physician was frustrated by the lack of insurance for fertility issues as
opposed to other procedures:
My 84-year-old mother who is pretty healthy . . . just had a
femoral artery dilated and angioplasty. And she’s on Medicare,
and . . . she really probably did not need this procedure. . . . [I]t
drives me crazy that Medicare will probably spend $30,000 or
$40,000 on what she’s just been through, she didn’t really need,
and yet I’ve had a 30-year-old woman with tubal factor
infertility who could easily have two children but she can’t
afford the $10,000 for the IVF cycle.88
Thus, the scope of insurance may be changing, though in which
direction is not yet clear. As knowledge about infertility increases, more
medical causes may become apparent, and treatment of the underlying
issues may be integrated with fertility care. For example, obesity
increases the incidence of infertility and fertility-related obesity
interventions can range from nutritional coaching to hormonal or other
drug interventions to IVF.89 Greater integration of the two, such as
requiring a weight-loss regimen before attempting IVF, may blur the
distinctions between fertility and non-fertility medical procedures.90
The most intriguing development along these lines involves the effect
of increased genomic information as more couples become aware of
hereditary conditions that could seriously impair the health of their
offspring and could be eliminated through use of IVF and genetic
screening.91 The result could increase the demand for IVF and increase
86. Scholars refer to this as “structural infertility” and explain that it “occurs when an individual
or couple desires to reproduce but must do so through means other than sexual intercourse because
of the social structure in which they self-identify. Single individuals and same-sex couples provide
examples of structural infertility.” Daar, supra note 20, at 24.
87. Interview with Physician One, supra note 65.
88. Interview with Physician Two, supra note 56.
89. See Renato Pasquali et al., Obesity and Infertility, 14 CURRENT OPINION ENDOCRINOLOGY
DIABETES & OBESITY 482, 482–84 (2007) (describing the complex role of obesity in infertility and
pregnancy outcomes).
90. See FERTILITY MARKET OVERVIEW, supra note 26, at 6 (describing potential responses to
obesity in intended parents).
91. See David Sable, The Seven Trends that Define the Future of IVF, FORBES (Feb. 28, 2015,
4:53 PM), http://www.forbes.com/sites/davidsable/2015/02/28/the-seven-trends-that-define-thefuture-of-ivf/.
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the pressure for insurance coverage of both the genetic screening and the
availability of IVF for those facing a significant possibility of passing on
disabling traits.92
Even without government mandates, health insurers, who will bear
the costs for children with medical complications or special needs, have
shown some inclination to expand coverage to include procedures that
reduce overall costs. These procedures may extend to genetic screening
as the ability to identify genetic risks increases, and may include at least
some rounds of IVF as studies show that insurance coverage contributes
to patient willingness to implant one embryo at a time, reducing the risks
(and costs) associated with multiples.93
The biggest unknown in this process, however, is how politics will
affect the ART industry. On the one hand, interest in offering insurance
coverage for fertility services is increasing as more couples delay
childbirth and face potential difficulties having children.94 This may
increase pressure on legislators to mandate coverage and on employers
to include IVF coverage options.95 On the other hand, if insurance costs
were to rise generally, employers might find IVF coverage a relatively
easy benefit to drop. Moreover, both factors may occur simultaneously,
with coverage (and coverage mandates) increasing more rapidly in large
urban areas and better educated tech centers where the age of first birth
is rising more rapidly, and coverage remaining limited in other parts of
the country.96
At present, insurance coverage for fertility services appears to be
rising gradually. A 2013 study indicated that sixty-five percent of

92. Judith Daar observes that the Affordable Care Act gives HHS the authority “to specify which
services and benefits are to be included within a benefit category as an essential health benefit.
Fertility care, for example, could be included as a benefit within the maternity care category.” Daar,
supra note 29, at 322.
93. See id. at 315–19, 323 (noting that patients in the U.S. and abroad who have access to some
form of insurance coverage for IVF deliver fewer multiples).
94. Bernard, supra note 22.
95. See Daar, supra note 29, at 321 (describing support for increased insurance coverage).
96. In addition, the pressure for employers to extend coverage may vary considerably. See Matt
McCue, OvaScience CEO Talks Apple, Facebook and the $9 Billion Fertility Market, FORTUNE
(Oct. 16, 2014, 11:54 AM), http://fortune.com/2014/10/16/fertility/ [https://perma.cc/7H7G-62FJ]
(“There is a trend in companies covering more fertility-related costs for employees; however, in the
U.S. it varies greatly by employer and state.”). For a discussion of the role of religious objections to
IVF in the failure to extend insurance coverage, see generally Carbone & Cahn, supra note 3. Where
anti-abortion restrictions, such as personhood amendments, are seen as restricting IVF, however,
those restrictions have lost at the polls, even in states such as Mississippi. See Jonathan F. Will,
Beyond Abortion: Why the Personhood Movement Implicates Reproductive Choice, 39 AM. J.L. &
MED. 573, 585 (2013).
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businesses with more than 500 employees will pay for an initial
evaluation by a fertility specialist, though only twenty-seven percent
cover IVF (up from twenty-three percent in 2012). Forty-one percent of
large employers cover drug therapies associated with infertility
treatments.97
And what about IVF costs for patients paying out-of-pocket—will
average prices for an IVF cycle trend upward or downward, or stay the
same? The long-term stability of the average cost of an IVF cycle might
actually mean that costs have decreased over time, however expensive it
may seem in today’s dollars. As Physician One emphasized, “they have
decreased a lot, when you look at twenty, thirty years ago, yes, it was
fifteen, twenty thousand dollars; it was much more difficult. And now it
has remained the same, so in actual dollars, it’s much cheaper.”98 This
physician stressed that the bulk of profits from fertility treatment go into
the pockets of other parties, including pharmaceutical providers, and that
fertility providers—and physicians in general—are not as well-off as
most would believe:
[W]hile the cost of being a physician is going up, the average
physician comes out with $250,000 of debt. . . . A lot of people
have this thing on their mind, that physicians are super-rich,
and . . . the average physician earns eighty-five, a hundred
thousand bucks. . . . Three elements are making the money
here[:] . . . the hospitals, the pharmaceutical [industry], and the
medical devices. . . . The doctors have been used as a scapegoat
in the health care system debate because the doctors, as I told
you, we’re not good collaborators, so it’s a weaker link.99
In the future, some fertility professionals believe that prices for IVF will
remain fairly stable. “[I]t’ll either have to stay the same or decrease. I
don’t think that people can carry an increase in the cost,” opined the
executive in a fertility management organization:
[I]f you look at third-parties, where patients are spending
twenty, thirty thousand for a single cycle . . . . I don’t think that
patients can afford more than that. And I do think that there’re
going to be more financial programs that come into effect, that

97. Bernard, supra note 22.
98. Interview with Physician One, supra note 65; see also The Costs of Infertility Treatment,
RESOLVE, http://www.resolve.org/family-building-options/making-treatment-affordable/the-costsof-infertility-treatment.html [https:// perma.cc/F7RV-CR64] (last visited Feb. 17, 2016) (supporting
Physician One’s assertions).
99. Id.
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help patients actually pay for it.100
If the market will not bear an increase in IVF cost, this leaves the
question of who will pay for innovations, and how. The executive in a
fertility-related nonprofit remarked:
Here’s the problem with all these great new things that are
gonna come down the pipe. They’re gonna add cost. . . . [If]
you’re gonna add on some of these things that could potentially
bring a standard old IVF cycle, with a few of these things
to . . . now be . . . twenty to twenty-five thousand? I just don’t
see it. So I think there’s gonna have to be some sort of cost
reduction at somewhere along the line.101
The executive at a for-profit fertility pharmaceutical corporation,
however, asserted that prices must drop:
Everybody wants to “grow the market.” They all want a bigger
piece of the pie. But the pie is only getting smaller. And the
consolidation is helping with some of that, in keeping the
volumes up inside the practices, and moving forward—but
eventually, you can’t consolidate any more. You just have to
become better at what you’re doing. And something has to
happen to the price of IVF for these practices to continue to
grow. . . . And this industry, these issues, these practices, are
extremely profitable. And they’ve done that over the years
because of the ability to set that price of managed care, where
they have a pretty good reimbursement going. The cash market
is just not gonna bear the price points that these physicians have
put on their services. . . . [L]ook at Dr. [Name] in upstate New
York, whose model has always been . . . “Cheap IVF.” . . . Dr.
[Name] is . . . basing his practice model on “Hey, rich people
can afford a $4,500 dollar cycle. Poor people can’t afford a
$15,000 dollar cycle. And as long as I’m doing a good job, I
don’t see the best success rates in the country, but as long as I’m
on par with the national average, and I offer IVF at 4,500
dollars, those richer couples are still going to come to me,
because why pay $13,000 dollars for a procedure you can have
done successfully for $4,500? They’re smart consumers. But if I
don’t put my price there, I lose all of that middle-income couples
[population].”102
Greater insurance coverage would almost certainly increase the
100. Interview with Management Corporation Executive, supra note 57.
101. Interview with Non-Profit Official, supra note 60.
102. Interview with Pharmaceutical Corporation Executive, supra note 62.

05 - Carbone Madeira.docx (Do Not Delete)

2016]

BUYERS IN THE BABY MARKET

3/23/2016 4:28 PM

93

supply of those seeking IVF, and it is likely to encourage further
industry consolidation. The question is whether it would also spur the
search for lower cost, higher volume services or whether increased
demand would further segment the industry, encouraging new
procedures with higher profit margins as well.
C.

The Future of Innovation

The future of reproductive medicine innovation has two dimensions:
(1) where will innovation occur, and (2) how will these innovations be
implemented? Increasingly, innovations are coming not from fertility
clinics but from entrepreneurial biotech startups such as OvaScience, and
may be just as likely to be developed and tested outside the United States
as inside national boundaries. Moreover, implementation of the
innovations on the horizon may overlap with consolidation.
Entrepreneurial companies may take advantage of consolidating clinics
to market their innovations first to larger fertility clinics, which have
greater patient volume as well as the financial and technological
resources to purchase and implement these innovations.
Innovation, which has traditionally occurred through university
research centers or individual physician initiatives, may increasingly
occur abroad or in more entrepreneurial start-ups that leverage
jurisdictional differences. What may propel research abroad is the
breakdown in the implicit American reproductive research bargain:
almost no federal funding and almost no limit on privately funded
research.103 Unlike other countries, American researchers do not require
advance approval before they begin preliminary research into assisted
reproduction.104 And unlike pharmaceutical companies, fertility clinics
have not needed advance regulatory approval before trying new
techniques such as IVF.105 This hands-off approach to reproductive
innovations ended, however, when the Food and Drug Administration
(FDA) asserted jurisdiction over cytoplasm transfers and cloning in the

103. See Kerry Lynn Macintosh, Brave New Eugenics: Regulating Assisted Reproductive
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 271 (noting that
the FDA claimed it had jurisdiction over “human cells used in therapy involving the transfer of
genetic material by means other than the union of gamete nuclei”).
104. Charo, supra note 38, at 507.
105. See Mohammad Reza Sadeghi, How Should We Deal with the Barrage of New Infertility
Treatments and Innovative Technologies?, 13 J. REPROD. & INFERTILITY 181, 181–82 (2012)
(describing rapid rate of innovation and lack of clinical trials and testing for new fertility
technologies).
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late 1990s.106
In 1996, the St. Barnabas Medical Center in New Jersey experimented
with an effort to “rejuvenate” aging eggs by adding cytoplasm obtained
from the eggs of younger women donors.107 The doctors, who had
limited research funds, simply tried the technique on their patients.108
The result produced thirty children worldwide, born using gametic
material from three parents.109 Two out of eighteen fetuses developed
Turner’s Syndrome, a chromosomal abnormality, and researchers
speculated that it could have come from the technique or from the
patient’s age.110 These children, however, did not inherit the donor DNA,
but at least two other children in the group did.111 Ethicists objected to
the prospect of germline genetic engineering—that is, the creation of
children using DNA from a third party who would pass on the donor
DNA to their own children112—and the FDA, alarmed at the use of an
untested technique of uncertain safety, asserted jurisdiction.113 The result
effectively shut down this type of research in the United States, at least
on humans.114
106. For a discussion of the FDA’s jurisdiction in such matters, see Richard A. Merrill & Bryan J.
Rose, FDA Regulation of Human Cloning: Usurpation or Statemanship?, 15 HARV. J.L. & TECH.
85, 102 (2001).
107. See Jody Lyneé Madeira, Conceivable Changes: Effectuating Infertile Couples’ Emotional
Ties to Frozen Embryos Through New Disposition Options, 79 UMKC L. REV. 315, 316 (2010).
108. Carbone, supra note 31, at 1920.
109. The process used a fertilized egg from the intended parents with nuclear DNA from the
intended mother and father, and added cytoplasm from a donor egg that would ordinarily contain the
donor’s mitochondrial DNA. Jason A. Barritt et al., Epigenetic and Experimental Modifications in
Early Mammalian Development: Part II, Cytoplasmic Transfer in Assisted Reproduction, 7 HUM.
REPROD. UPDATE 428, 428 (2001).
110. See Macintosh, supra note 103, at 272 (reviewing the safety debate).
111. Barritt et al., supra note 109, at 429–30. The cytoplasm was intended to strengthen the
function of, rather than replace, the cytoplasm of the egg from the intended mother, and the child
would not necessarily express the donor’s DNA. Id. at 433. This process can be used with minimal
or no transfer of mitochondrial DNA from the donor. See Jacques Cohen et al., Birth of Infant After
Transfer of Enucleate Donor Oocyte Cytoplasm into Recipient Eggs, 350 LANCET 186, 187 (1997).
112. See John A. Robertson, Oocyte Cytoplasm Transfers and the Ethics of Germ-Line
Intervention, 26 J.L. MED. & ETHICS 211, 211–13 (1998) (describing the various techniques).
Researchers did find mitochondrial DNA from the donor in two of the children born using the St.
Barnabus procedure, but not the others. See Kim Tingley, The Brave New World of Three-Parent
I.V.F., N.Y. TIMES (June 27, 2014), http://www.nytimes.com/2014/06/29/magazine/the-brave-newworld-of-three-parent-ivf.html [https://perma.cc/BCV3-RPV5].
113. See Judith Daar, Multi-Party Parenting in Genetics and Law: A View from Succession, 49
FAM. L.Q. 71, 74 (2015) (observing that after the FDA said in 2001 that any further use of
cytoplasmic injection would require an Investigational New Drug application, the practice ceased
throughout the United States).
114. It has, however, been done in the United States in monkeys. See David Cyranoski, DNASwap Technology Almost Ready for Fertility Clinic, NATURE (Oct. 24, 2012),
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The farthest reaching developments have occurred abroad. In
February 2015, Parliament authorized the United Kingdom regulatory
body that oversees assisted reproduction to license clinics that wished to
use three-party IVF to eliminate the risk of mitochondrial disease.115 The
authorization is more restrictive than the St. Barnabas procedures used in
the 1990s in that it is designed to deal only with mitochondrial disease,
not the problems associated with aging eggs.116 Nonetheless, it allows
the research to proceed to human trials that will produce children.
In the United States, the FDA has started discussion of whether the
procedure should be allowed here.117 Before Parliament acted, the United
Kingdom required animal testing and human experimentation on
embryos up until the fourteen-day stage.118 The FDA would similarly
require clinical trials before authorizing the procedure, and the funding
for such measures would presumably have to come from private
sources.119 The lack of such private funding sources is what shut down
developments when the FDA asserted jurisdiction over the St. Barnabas
procedures, and it is unclear whether that funding now exists.120
http://www.nature.com/doifinder/10.1038/nature.2012.11651 [https://perma.cc/RE3B-PMYH]. This
research continues in the lab, without use of public funds. See Tingley, supra note 112.
115. James Gallagher, UK Approves Three-Person Babies, BBC NEWS (Feb. 24, 2015),
http://www.bbc.com/news/health-31594856 [https://perma.cc/YN9Y-JXMW].
116. See Tingley, supra note 112.
117. See Dina Fine Maron, Making Babies with 3 Genetic Parents Gets FDA Hearing, SCI. AM.
(Feb. 25, 2014), http://www.scientificamerican.com/article/making-babies-with-3-genetic-parentsgets-fda-hearing/ [https://perma.cc/AT8U-SLUB]. As this Article was going to press, the U.S.
Institute of Medicine issued a report recommending that clinical investigations be authorized, but
limited to the creation of boys, who could not transmit the donor genes to offspring. The report
suggested guidelines for such investigations, including a requirement that the investigators secure
funding for long-term monitoring of children born through use of the procedure. NAT’L ACADS. OF
SCI., ENG’G & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND
POLICY CONSIDERATIONS (2016) [hereinafter MITOCHONDRIAL REPLACEMENT TECHNIQUES],
http://iom.nationalacademies.org/reports/2016/Mitochondrial-Replacement-Techniques
[https://perma.cc/GB78-QJXP]. Nonetheless, a provision in the Consolidated Appropriation Act of
2016 may bar the procedure even if the FDA approves it. Joel Achenbach, Ethicists Approve ‘3
Parent’ Embryos to Stop Diseases, but Congressional Ban Remains, WASH. POST (Feb. 3, 2016),
https://www.washingtonpost.com/news/speaking-of-science/wp/2016/02/03/to-prevent-diseaseethicists-approve-creation-of-embryos-with-three-genetic-parents/ [https://perma.cc/W2UX-6MDP].
118. See Gallagher, supra note 115.
119. See J. Ravindra Fernando, Three’s Company: A Constitutional Analysis of Prohibiting
Access to Three-Parent In Vitro Fertilization, 29 NOTRE DAME J.L. ETHICS & PUB. POL’Y 523, 527
(2015) (describing FDA approval process that includes searching review of the method’s safety and
efficacy as well as satisfactory completion of human trials).
120. See Tingley, supra note 112 (discussing funding available for stem cell research). “While the
creation of human embryos for research is not prohibited under federal law in the United States
(although some states are more restrictive), neither FDA nor any other agency of the U.S.
Department of Health and Human Services can financially support such research where embryos are
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In the meantime, other research is moving abroad, hoping to establish
that medical procedures work in other jurisdictions before attempting to
use them in the United States. The owners of biotech start-up
OvaScience have expressed their frustration with U.S. procedures. They
observe that there have not been any significant improvements in IVF in
more than two decades.121 The most pressing issues involve egg quality,
such as aging eggs that fail to produce pregnancies or women who for a
variety of reasons fail to produce mature eggs capable of reproducing.
New experimentation builds on the earlier procedures; some scientists
would like to refine the process of cell “rejuvenation,” perhaps adding
some of the intended mother’s own, healthy mitochondria to her eggs.122
Other experimenters propose taking a woman’s immature eggs and
allowing them to develop outside her body, or using a woman’s stem
cells to create entirely new eggs.123 Extracting stem cells—or immature
eggs—from a patient might be cheaper and less intrusive than extracting
mature ova, and it would extend women’s reproductive lives. Scientists
expect egg production to be the new frontier for assisted reproduction.124
In 2013, OvaScience proposed to commercialize a new treatment it
called “Augment” that would boost egg quality by using a woman’s own
mitochondria.125 When it announced plans to do so, the FDA asserted
that rather than treat the process as a medical procedure, subject to light
regulation, it would subject the treatment to its more rigorous standards
for drug development.126 The company’s share price tanked as a result,

destroyed, discarded, or subjected to risks with no prospect of medical benefit for the embryo.”
George Dvorsky, US Experts Say Three-Parent Babies Are Okay—Just No Girls, GIZMODO (Feb. 3,
2016, 6:11 PM), http://gizmodo.com/us-experts-say-three-parent-babies-are-okay-just-no-gir1756947506 [https:// perma.cc/64Z5-DGRG] (quoting MITOCHONDRIAL REPLACEMENT
TECHNIQUES, supra note 117, at 24).
121. Don Seiffert, OvaScience Advances Fertility Treatments Quickly Outside the U.S., BOS. BUS.
J.,
http://www.bizjournals.com/boston/blog/bioflash/2014/09/ovascience-advances-fertilitytreatments-quickly.html?s=print [https://perma.cc/F9UB-ZU2J] (last updated Sept. 2, 2014, 3:05
PM).
122. See Jonathan L. Tilly & David A. Sinclair, Germline Energetics, Aging, and Female
Infertility, 17 CELL METABOLISM 838, 838–50 (2013) (describing rejuvenation of eggs).
123. See Dori C. Woods & Jonathan L. Tilly, The Next (Re)Generation of Ovarian Biology and
Fertility in Women: Is Current Science Tomorrow’s Practice?, 98 FERTILITY & STERILITY 3, 6–7
(2012) (describing the potential for taking egg stem cells and using them to develop new mature
eggs).
124. Anita Slomski, Hard to Conceive, PROTO (Nov. 5, 2014), http://protomag.com/articles/ivfhard-to-conceive [https://perma.cc/5HLZ-W3US].
125. AumentSM Treatment, OVASCIENCE, http://www.ovascience.com/treatments/augment
[https://perma.cc/KB2B-KM9E] (last visited Feb. 23, 2016).
126. Seiffert, supra note 121.
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but it dealt with the setback by moving commercialization abroad.127
Today, Augment is still not available in the United States, but in May
2015, OvaScience announced the birth of the first child born through use
of the procedure in Toronto, Canada.128 It believes that the global market
is large enough that it makes more sense to test the effectiveness of its
products through human use and testing abroad. OvaScience’s chief
scientific officer observed, “People get hung up on, it’s a U.S. thing
versus outside (the U.S.), I think of it as, where are the patients?”129 And
he concluded that, on a global basis, ninety percent of the IVF treatments
occur abroad.130
OvaScience represents a major change in the source of innovation in
assisted reproduction. The company thinks of itself as an entrepreneurial
firm, intent on changing the way innovation in fertility treatments
occurs.131 It seeks to disrupt, not exploit, existing markets.132 It has
attracted venture capital investors,133 and it is a publically traded
corporation.134
Both groups—private equity investors and
shareholders—tend to focus on short term results. If the company is
successful, it may be acquired by a larger operation; if its early products
founder, it may soon be out of business. In this context, the company
approaches regulations as obstacles to circumvent.
The FDA, which comprehensively regulates drugs, has typically taken
a different approach to medical procedures and human tissue, and thus

127. Alison Motluk, IVF Booster Offered in Canada But Not in US, CTR. FOR GENETICS & SOC’Y
(Jan. 14, 2015), http://www.geneticsandsociety.org/article.php?id=8304 [https://perma.cc/F3M672RP]; OvaScience’s Fertility Technology in Limbo After FDA Demands IND Filing, EP VANTAGE
(Sept.
12,
2013),
http://www.epvantage.com/Universal/View.aspx?type=Story&id
=455479&isEPVantage=yes [https://perma.cc/K8HC-KWRM].
128. First Baby Born with OvaScience’s Augment Fertility Treatment, OVASCIENCE INC. INV.
REL. (May 7, 2015), http://ir.ovascience.com/mobile.view?c=251343&v=203&d=1&id=2045382
[https://perma.cc/4VXC-6XMW].
129. Seiffert, supra note 121.
130. Id.
131. Id.; see also OvaScience Chief Executive Officer Selected Entrepreneur of the Year 2013
Finalist for New England by Ernst & Young, OVASCIENCE (June 3, 2013),
http://www.ovascience.com/news/article/ovascience-chief-executive-officer-selected-entrepreneurof-the-year-2013-f [https://perma.cc/Y8JU-5SJ3] (highlighting the successes of its executives as
entrepreneurs).
132. Seiffert, supra note 121.
133. OvaScience,
CRUNCHBASE,
https://www.crunchbase.com/organization/ovascience
[https://perma.cc/XX4L-5GHL] (last visited Feb. 5, 2016).
134. Don Seiffert, Clinical Data May Not Win over OvaScience Skeptics—but Revenue Will, BOS.
BUS.
J.
(June
17,
2015,
12:11
PM),
http://www.bizjournals.com/boston/blog/
bioflash/2015/06/clinical-data-may-not-win-over-ovascience.html [https://perma.cc/Q2W8-WHPL].
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has had relatively limited involvement in IVF.135 It nonetheless intended
its assertion of jurisdiction over human cloning and the St. Barnabas
cytoplasm procedure to have an in terrorem effect;136 that is, the mere
suggestion that the FDA would require review before the procedure
could be done shut down such experimentation in the United States.137
This has taken place in large part because of the lack of funding for
testing that would satisfy the FDA’s safety and efficacy concerns. Such
testing in the pharmaceutical arena is enormously expensive, and it has
tended to focus private efforts on the development of “blockbuster”
drugs, with large payoffs for the developers.138 The market for assisted
reproduction is not only more limited; the lack of insurance coverage
makes it harder to realize the types of profits that fuel pharmaceutical
research.
OvaScience dealt with the FDA assertion of jurisdiction by moving
abroad and for the moment, the company and the agency are at
loggerheads.139 OvaScience hopes that, by demonstrating success
abroad, it will persuade the FDA to relent.140 The FDA, which has
successfully shut down this type of research in the past,141 risks
becoming irrelevant if the effect of its efforts are to push reproductive
research abroad. But when OvaScience announced the birth of a baby
born through use of Augment in Toronto, Canada, its share prices fell
because industry analysts expressed concern about the lack of
appropriate testing.142 An analysis of the company’s prospects, however,
indicated that while the clinical data is not yet winning over skeptics,
“revenue will.”143 The company’s business model effectively requires
that it position itself to succeed in the global market if it wishes to

135. The FDA’s assertion of authority is itself controversial. See Macintosh, supra note 103, 273–
74; Merrill & Rose, supra note 106.
136. Merrill & Rose, supra note 106, at 100 (“The predictable in terrorem effect of these
statements was almost certainly intended . . . .”).
137. Macintosh, supra note 103, at 270.
138. See generally June Carbone, Ethics, Patents and the Sustainability of the Biotech Business
Model, 17 INT’L REV. L. COMPUTERS & TECH. 203 (2003) (describing business model of drug
development).
139. Taryn Hillin, Why an Incredible New Method to Extend Fertility Is off Limits in the U.S.,
FUSION (Aug. 4, 2015, 5:54 AM), http://fusion.net/story/164309/new-fertility-treatment-ovascienceaugment-ivf-eggs/ [https://perma.cc/2YMY-S2C5].
140. See Seiffert, supra note 121.
141. Daar, supra note 113, at 74 (discussing the FDA’s shut down of the earlier experimentation
with cytoplasmic transfers).
142. Seiffert, supra note 134.
143. Id.
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establish itself in the United States.144 In the meantime, however,
OvaScience’s share price has been incredibly volatile, ranging from a
high of $55.69 per share to a low of $7.90 per share over a fifty-two
week period.145
Once innovations are ready for the market, companies such as
OvaScience will take advantage of larger clinic networks, produced
through consolidation, to distribute innovations. As a result, larger
clinics will be able to offer their patients higher-end services at more
competitive prices. According to a top fertility nonprofit official, “people
who are paying out-of-pocket . . . are requiring and requesting a higherquality end result.”146 This official sees innovations occurring not in the
sense of a “big breakthrough on the medical side” but in “the devices,
the testing.”147 But because larger firms “tend to be more willing to be
test sites . . . or they’re early adopters, . . . widespread use on some of
these things is gonna take a long time.”148
In the early stages, the latest scientific advances will cost more,
require better trained, more sophisticated staff and carry higher profit
margins on the performance of what is likely to be, at least initially, a
small number of procedures. Yet, these new procedures will offer some
prospective parents their only chance of having a genetically related
child. The high-end market may, accordingly, remain lucrative.149

144. Indeed, in an effort to reassure its investors, OvaScience emphasizes its international reach,
with new agreements to distribute Augment in Spain, Latin America, Japan, and the U.K. Its press
releases underscore the size of its partners, highlighting its relationship with IVI Valencia, “a
leading IVF clinic in Spain that is part of the IVI Group of 38 clinics spanning nine countries, which
is the largest IVF clinic network in the world” and the largest group of clinics in Japan. Press
Release, OvaScience Reports Second Quarter 2015 Financial Results (Aug. 10, 2015),
http://ir.ovascience.com/phoenix.zhtml?c=251343&p=irol-newsArticle&ID=2078484
[https://perma.cc/CNN8-8LMY].
145. See Ovascience Inc. Analyst Price Target Update, AM. TRADE J. (Oct. 16, 2015),
http://www.americantradejournal.com/ovascience-inc-analyst-price-target-update/6127536/
[https://perma.cc/P6K9-4BV2].
146. Interview with Non-Profit Official, supra note 60.
147. Id.
148. Id.
149. SPAR, supra note 7, at 65 (observing there is still considerable room at the top end of the
market). With greater fertility tourism, this will be true whether or not the procedure is permitted in
a given jurisdiction. If the procedure proves safe and popular abroad, pressure will build to
introduce it into the United States. If not, American clinics may feel greater pressure to have foreign
offices in jurisdictions that allow the procedure. In either case, larger, more flexible, and multijurisdictional clinics will be in a better position to leverage regulatory differences for their own
benefit.

05 - Carbone Madeira.docx (Do Not Delete)

100
D.

WASHINGTON LAW REVIEW

3/23/2016 4:28 PM

[Vol. 91:71

Globalization, Brokers, and Network Creation

These forces—globalization, increasing economies to scale, and the
potential to leverage jurisdictional differences—may ultimately come
together to remake assisted reproduction. For providers, economies of
scale are prompting the type of consolidation going on across the
medical profession; larger entities in turn may try to serve a larger
clientele though the right mix of higher volume, lower cost services, and
high-end developments for those who can afford them.
At the same time, consumers are becoming more sophisticated in their
search for more affordable—or more custom-tailored—products.150
Increasingly, they are recognizing jurisdictional differences in medical
care pricing, quality, and service availability.151 Medical tourism,
defined as “the travel of patients from the ‘home country’ to the
‘destination country’ for medical treatment,” is a rapidly growing multibillion-dollar industry involving thousands of patients from the United
States alone.152 The Centers for Disease Control and Prevention (CDC)
estimates that 750,000 U.S. residents travel abroad for health care each
year.153 In total, the 2014 worldwide market for medical tourism was
estimated to be between $38.5 billion and $55 billion.154
American patients travel abroad for health care for the same reasons
that companies locate some of their activities overseas: prices may be
more affordable and restrictions may be less onerous.155 And rather than
try to stem the travel aboard, American medical providers have
sometimes sought to take advantage of the opportunities for their own
benefit. For example, Johns Hopkins Medical International entered into a
joint venture with Panama City’s Hospital Punta Pacífica, which gave
the Panamanian facility “the advantages of an internationally recognized
brand and access to the expertise of U.S. medical practitioners regarding

150. Indeed, preliminary research in 2010 indicates that patients are using the internet to seek out
care abroad, typically after having sought treatment in their home country. See Eric Blyth, Fertility
Patients’ Experiences of Cross-Border Reproductive Care, 94 FERTILITY & STERILITY e11, e14
(2010).
151. Id. at e12–e13 (indicating that patients are motivated both by factors such as cost and waiting
time and by availability of services such as oocyte donation).
152. I. Glenn Cohen, Circumvention Tourism, 97 CORNELL L. REV. 1309, 1311 (2012).
153. Medical Tourism, CTR. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
features/medicaltourism/ [https://perma.cc/9LZU-WYWT] (last visited Feb. 5, 2016).
154. Joseph L. Muzaurieta, Surgeries and Safaris: Creating Effective Legislation Through a
Comparative Look at the Policy Implications, Benefits, and Risks of Medical Tourism for the
American Patient, 29 TEMP. INT’L & COMP. L.J. 115, 116 (2015).
155. Id. at 117.
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best practices and patient safety.”156 In addition, some insurance plans
are considering (or in a few cases have already implemented) programs
that would incentivize or mandate their insured patients to use medical
tourism.157 There have also been proposals to allow Medicare and
Medicaid beneficiaries to use their benefits abroad, given the potential
cost savings involved for government programs.158
On a smaller scale, patients have also engaged in “fertility tourism”
for similar reasons: to take advantage of lower prices abroad and/or to
circumvent restrictions.159 International surrogacy, particularly in India,
has perhaps attracted the most attention—and criticism.160 The price
difference between services stateside and overseas creates enormous
incentives to move surrogacy abroad. In India, for example, a surrogate
who successfully gives birth typically makes between $5000 and $6000,
“an amount that exceeds a typical salary for several years of ordinary
labor in India.”161 The clinic, in turn, charges American medical tourists
$15,000 to $20,000 for the entire process, which constitutes “between a
third and a fifth of what clients would pay for a similar service in the
United States.”162 It also generates more than $500 million per year in
revenues for India, constituting a respectable part of that country’s
overall economic growth.163
Moreover, since many countries ban surrogacy, or limit it to married,
156. U.S. INT’L TRADE COMM’N, CARIBBEAN REGION: REVIEW OF ECONOMIC GROWTH AND
DEVELOPMENT, at xix (2008).
157. I. Glenn Cohen, Protecting Patients with Passports: Medical Tourism and the PatientProtective Argument, 95 IOWA L. REV. 1467, 1473 (2010).
158. See generally DEAN BAKER & HYE JIN RHO, CTR. FOR ECON. & POL’Y RES., FREE TRADE IN
HEALTH CARE: THE GAINS FROM GLOBALIZED MEDICARE AND MEDICAID (2009) (outlining a plan
for globalizing Medicare and Medicaid programs); Jennifer Conley, Medicare and Medical
Tourism: Saving Medicare with a Global Approach to Coverage, 21 ELDER L.J. 183, 218 (2013)
(“Medical tourism is a viable way for Medicare to rein in out-of-control health care spending and
costs.”).
159. See, e.g., Blyth, supra note 150, at e11; Cohen, supra note 152, at 1323 (observing that
reproductive restrictions have prompted significant amounts of medical tourism).
160. See, e.g., Lisa C. Ikemoto, Reproductive Tourism: Equality Concerns in the Global Market
for Fertility Services, 27 LAW & INEQ. 277, 282 (2009) (“The most troubling aspects of reproductive
tourism arise from the use of third parties who furnish gametes and from surrogates who gestate
babies for others. In fact, the strongest critics of these practices use the term ‘trafficking’ rather than
‘tourism.’”).
161. Cohen, supra note 152, at 1324–25; see also Pamela Laufer-Ukeles, Mothering for Money:
Regulating Commercial Intimacy, 88 IND. L.J. 1223, 1272 (2013) (“Indian surrogates, in contrast to
[American surrogates], demonstrate a very low level of education and economic earning power.”).
162. Cohen, supra note 152, at 1325.
163. Michele Goodwin, Reproducing Hierarchy in Commercial Intimacy, 88 IND. L.J. 1289, 1292
(2013) (noting that $500 million a year of that revenue stays in India).
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heterosexual couples,164 some couples find that they can have genetically
related children only by going abroad.165 Many couples whose home
countries provide no access to surrogacy come to the United States.166
Stuart Bell, the chief executive of Growing Generations, a Los Angeles
surrogacy agency, reported that four years ago, “only about 20 percent of
its clients came from overseas, but now international clients are more
than half.”167 Other agencies report similar trends.168
Practices such as surrogacy and egg donation are controversial
because of the risk of exploitation of the women involved and/or because
of ethical objections to the practice wherever it occurs.169 This kind of
travel—to evade restrictions in the home country—has been termed
“circumvention tourism.”170 The expansion of fertility tourism, however,
also involves factors common to globalization generally: efforts to
leverage differences in price,171 to receive care from high quality,
experienced and successful specialists,172 to access newly developed or
niche treatments not widely available,173 or to find a cultural milieu more
supportive than that in the home country.174 Cutbacks in insurance
164. See Cohen, supra note 152, at 1323. China, France, Germany, Italy, Japan, Pakistan,
Portugal, Saudi Arabia, Spain, and Turkey ban all forms of surrogacy while other countries and
some U.S. states prohibit only commercial surrogacy. Joseph Chamie & Barry Mirkin, Surrogacy:
Human Right or Reproductive Exploitation?, YALE GLOBAL ONLINE (Oct. 28, 2014),
http://yaleglobal.yale.edu/content/surrogacy-human-right-or-reproductive-exploitation
[https://perma.cc/26W7-N4ND].
165. See Debora Spar, Reproductive Tourism and the Regulatory Map, 352 NEW ENG. J. MED.
531, 531 (2005).
166. Tamar Lewin, Coming to U.S. for Baby, and Womb to Carry It: Foreign Couples Heading to
America
for
Surrogate
Pregnancies,
N.Y.
TIMES
(July
5,
2014),
http://www.nytimes.com/2014/07/06/us/foreign-couples-heading-to-america-for-surrogatepregnancies.html [https://perma.cc/7X8P-5JWT].
167. Id.; see also Blyth, supra note 150, at e11.
168. Lewin, supra note 166; see also Blyth, supra note 150, at e14 (reporting increase in internet
searches for surrogacy agencies).
169. Ikemoto, supra note 160, at 130.
170. Cohen, supra note 152, at 1311–12.
171. Lack of insurance coverage tends to increase the willingness to go abroad. See Ikemoto,
supra note 160, at 298.
172. For example, “success rates” were a factor for some patients. See Blyth, supra note 150, at
e13. Kimberly Mutcherson observes further that the “reputation that the United States has earned as
a nation with wide accessibility to high-quality fertility care, for those who can afford the equally
high price tag that accompanies such care” attracts patients here. See Kimberly M. Mutcherson,
Welcome to the Wild West: Protecting Access to Cross Border Fertility Care in the United States,
22 CORNELL J.L. & PUB. POL’Y 349, 364 (2012).
173. See, e.g., supra Section II.C (discussing Augment, which is only available outside of the
United States).
174. See Ikemoto, supra note 160, at 286–87 (noting existence of clinics and destinations that
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coverage or the adoption of more restrictive regulations may spur
increased interest in reproductive travel.175 For example, when Italy
adopted Europe’s most restrictive laws, some Italian doctors simply
moved their clinics across the border to Switzerland and the international
clientele in Spain grew substantially.176 Today, cross-border fertility
travel in Europe is robust,177 and most observers expect it to continue to
grow.178
What remains to be seen is whether the globalization of ART will also
reduce prices. The Low-Cost IVF Foundation, a Swiss non-profit, is
seeking to develop fertility treatments that could assist women in the
developing world. It is currently working with Zambia’s health ministry
to set up an IVF program in Africa that would use clomiphene citrate
(Clomid), a drug that provides a modest boost to ovulation and costs just
$12 per attempt, instead of standard injectable gonadotropin drugs used
in the United States that cost thousands per cycle.179 Though Clomid
might not be as effective as injectable gonadotropins, for some women
its lower price may mean the difference between access to some
treatment and no treatment at all. Belgian researchers have experimented
with cheaper equipment that produced results comparable to those from
pricier, standard labs.180 And American doctors are attempting to
streamline the egg collection process, hoping to cut IVF costs in half for
most patients.181 As with Augment, biotech start-ups have begun to
emphasize their support for same-sex couples).
175. The Guardian commented at the height of the recession:
As the NHS cuts back on free treatment for the childless, lumping IVF with tattoo removal as
an act of kindness rather than treatment for a disease, the competitive prices of private clinics
overseas compared with their UK rivals will look ever more tempting. This weekend a number
of them will be touting for business at the Fertility Show, now in its second year, at London’s
Olympia.
Sarah Boseley, Fertility Becomes Big Business as NHS Cuts Back on Treatment, GUARDIAN (Nov.
5,
2010),
http://www.theguardian.com/society/2010/nov/06/fertility-treatment-foreign-clinics
[https://perma.cc/7D8V-SCZV].
176. Richard F. Storrow, Quests for Conception: Fertility Tourists, Globalization and Feminist
Legal Theory, 57 HASTINGS L.J. 295, 325 n.134 (2005) (citing Tamsin Smith, Fertility Laws
Frustrate Italians, BBC NEWS (Aug. 9, 2004), http://news.bbc.co.uk/2/hi/europe/3548242.stm
[https://perma.cc/94DF-4L2U]).
177. See Storrow, supra note 176, at 296–97.
178. Mutcherson, supra note 172, at 355.
179. Maybe Babies, ECONOMIST (July 19, 2014), http://www.economist.com/news/international/
21607881-vitro-fertilisation-once-seen-miraculous-now-mainstream-rich-countries-soon
[https://perma.cc/Q9U9-KS7B].
180. Id.
181. Great Expectations, ECONOMIST (Oct. 25, 2014), http://www.economist.com/news/scienceand-technology/21627560-new-procedure-may-halve-cost-vitro-fertilisation-great-expectations
[https://perma.cc/JY93-4WTQ]. Indeed, the efforts of the Low Cost Foundation also focus on egg
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create innovative procedures that have already been approved for use
abroad, though not in the United States.182
These developments suggest that ART will increasingly be seen as a
global phenomenon. Innovations may come from around the world, and
new developments may target diverse patient groups with varying needs
and abilities to pay. Yet, these developments are still in their infancy,
driven by innovative individual researchers and accessed by enterprising
patient-consumers who seek out the treatments. And the services that
grow the quickest are those with funding that is most readily available
from better-off patients.183 Observers wonder whether fertility tourism,
like medical tourism in general, will benefit from increased numbers of
international brokers who can attest to quality, determine safety, and
advise patients, or whether patients will become prey to less scrupulous
operators, precisely because of the lack of the third parties such as
insurance companies and government regulators.184 Today, the emerging
market for brokers tends to focus on the supply of sperm, eggs, embryos,
and surrogates, although that may change with the availability of three
parent IVF in the UK or sex selection procedures in the United States.185
Indeed, even within the United States, separate agencies that do not
necessarily provide fertility treatments themselves often recruit sperm
and egg donors and surrogates.186

collection. Its methods involve fewer drugs, less artificial stimulation of the woman’s ovaries, which
both reduced costs and the physical and emotional damage to women from egg collection. While the
initial results may be lower success rates, the researchers are optimistic that over the long term, the
results may become comparable. See Boseley, supra note 175.
182. Great Expectations, supra note 181.
183. The Low Cost Foundation, for example, though it is partnering with an African Health
Minister and has support from the World Health Organization, has struggled for funds. The
Guardian, after interviewing Foundation researchers, observed, “[t]he only money for now is in the
cash registers of the burgeoning commercial clinics around the globe – and it’s coming from
patients who may have sold or mortgaged all they have in the world for the chance of a baby.”
Boseley, supra note 175.
184. A U.K. expert on cross-border reproductive services, for example, advises that Spain is
“very good,” and the Czech Republic has labs that are inspected in accordance with high standards.
But she recommends against going to the Ukraine or to Greece, where the regulatory body has not
gotten off the ground because of a lack of funding. Id.
185. Ikemoto, supra note 160, at 287 (emphasizing that reproductive services take place in a
context broader than the doctor-patient relationship); see also id. at 291–92 (describing role of
brokers in facilitating international services).
186. KARA W. SWANSON, BANKING ON THE BODY: THE MARKET IN BLOOD, MILK, AND SPERM
IN MODERN AMERICA 199 (2014) (observing that most sperm banks and egg donor agencies are forprofit enterprises, selling over the internet, and focused more on recruiting patients than serving
doctors). See generally RENE ALMELING, SEX CELLS: THE MEDICAL MARKET FOR EGGS AND
SPERM (2011) (providing a comprehensive account of the recruitment of egg and sperm donors).
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Nonetheless, connections established across all parts of the fertility
business may ultimately contribute to a more globalized industry. First,
individual clinics increasingly see the internet as a source of patients,
and websites are designed to appeal to international patient audiences
and to those seeking services, such as sex selection, that are not
universally available.187 These appeals in turn contribute to word-ofmouth information—and to satisfied customers who help recruit
others.188 They may also contribute to niche markets for certain
procedures, such as sex selection, which is widely available in the
United States or mitochondrial transfer in the U.K.189 Second, as clinics
become larger, they may establish multi-jurisdictional partnerships or
affiliations. Lisa Ikemoto, for example, describes a relationship between
an American clinic and a Romanian lab, which recruited egg donors in
Romania, had the eggs fertilized in Bucharest and shipped back to the
United States, allowing the patient to realize savings both in the price of
the eggs and the medical procedures done abroad.190 She also mentions a
Danish clinic with centers in two Danish cities, Lithuania, and several
African countries.191 The Fertility Institutes’ homepage lists offices in
New York and Los Angeles, a presence in the United States, Mexico,
and India, and a network of over 240 associated U.S. and international
fertility centers.192 Third, increasing numbers of brokers, whether thirdparty internet sites, travel agencies, or fertility specialists offer to provide
information or arrange trips involving clinics abroad.193 Such brokers
have fueled the growth of international surrogacy and egg donation, and
187. Ikemoto, supra note 160, at 285–89; Blyth, supra note 150, at e13–14.
188. See Blyth, supra note 150, at e14 (discussing the importance of internet information in
prompting cross-border care).
189. Meredith Leigh Birdsall, An Exploration of “The ‘Wild West’ of Reproductive Technology”:
Ethical and Feminist Perspectives on Sex-Selection Practices in the United States, 17 WM. & MARY
J. WOMEN & L. 223, 226 (2010) (describing that more and more couples from other countries are
coming to the United States for sex-selection procedures that they are denied at home); see also
supra notes 115–20 and accompanying text (describing FDA responses to U.K. authorization of
three parent IVF to address mitochondrial disease).
190. Ikemoto, supra note 160, at 290.
191. Id.
192. FERTILITY
INSTS.,
http://www.fertility-docs.com/about-us/clinics-and-staff.php
[https://perma.cc/F8LU-5H46] (last visited Feb. 5, 2016); International Programs, FERTILITY
INSTS.,
http://www.fertility-docs.com/programs-and-services/international-programs.php
[https://perma.cc/K6PL-5MF7] (last visited Feb. 9, 2016); see also PAC. FERTILITY CTR.,
http://www.pacificfertilitycenter.com/the-center/infertility-center
[https://perma.cc/Y9BT-Z5M7]
(last
visited
Feb.
5,
2016);
International
Patients,
PAC. FERTILITY CTR.,
http://www.pacificfertilitycenter.com/treatment-care/international-patients [https://perma.cc/TA6VZ3A6] (last visited Feb. 5, 2016) (describing itself as having an independent affiliate in Japan).
193. Ikemoto, supra note 160, at 291–92.

05 - Carbone Madeira.docx (Do Not Delete)

106

WASHINGTON LAW REVIEW

3/23/2016 4:28 PM

[Vol. 91:71

they could help fuel reproductive tourism more generally.194
CONCLUSION
Larger entities, better-established networks, more global clientele, or
greater use of brokers may offer greater flexibility. Fertility clinics may
need to become more nimble in adopting new technologies, acquiring
the ability to custom tailor services to meet client demand, and
functioning in markets that may simultaneously reward less expensive
approaches that can generate greater volume and high-end products for
those who can pay for them. David Sable observes that:
I have seen countless business plans over the past couple of
years describing various combinations of IVF centers in
different parts of the country merging, gaining economies of
scale, trying to maintain pricing power and protecting quality
branding. This trend . . . will accelerate as the market expands
and consumer decisions are made less by individual patients and
more by a combination of large insurers assembling networks
and Uber/Open Table/Zoc Doc aggregators efficiently helping
patients find an appropriate clinic. As has occurred in many
areas of medicine, business will move to big purchaser
(insurer/payor/patient purchasing service) buying from big
provider (hospital/mega clinic[]).195
These developments suggest a market that will be even more
segmented in the future. It may involve clinics that scan the globe for
new developments that can be implemented in sophisticated, high profitmargin offices while referring more cost-conscious patients abroad. At
the same time, innovation may come from a mix of governmentsponsored and privately-initiated research. Ironically, governmentsupported research may be most critical to the low cost procedures with
the potential to expand care while private investment stakes out the
lower volume, but higher profit-margin innovations. And the innovations
may come from across the globe. For example, in September 2015, the
French announced that they had produced human sperm in a lab for the
194. Id.; see also Nicole Grather & Adam May, Going Global for a Family: Why International
Surrogacy
Is
Booming,
AL
JAZEERA
AM.
(May
12,
2014,
7:30
PM),
http://america.aljazeera.com/watch/shows/america-tonight/articles/2014/5/12/going-globalforafamilywhyinternationalsurrogacyisbooming.html [https://perma.cc/2LUY-U39H] (describing
the role of brokers in the growth of fertility tourism); Jennifer Rimm, Booming Baby Business:
Regulating Commercial Surrogacy in India, 30 U. PA. J. INT’L L. 1429, 1456–59 (2009) (describing
the positive and negative roles of agencies in commercial surrogacy).
195. Sable, supra note 91.
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first time, and a French biotech start-up sought a patent for the process
jointly with French National Center for Scientific Research.196
These changes should ultimately remake not just the availability of
fertility treatments, but the nature of the doctor-patient relationship.
Administrators will need to be both medical professionals and business
men and women. Their patients will also need to be consumers, able to
shop the most appropriate and affordable treatments. States interested in
securing the safety of their citizens will need to be aware of international
as well as national developments. At the center of these developments
will be information flows—how should we conceive of what doctors
need to know and to tell patients versus what the patients can be
expected (for better and worse) to find out on their own? With an
international race to invest, profit, evade regulatory restrictions, and
realize the future, the doctor-patient relationship will require ever more
sophisticated ways to determine safety and preserve the capacity for
meaningful choice. The physicians’ remarks quoted above illustrate that
they are already conscious of the shifts that the fertility industry is
currently experiencing and will continue to experience in the future. But
such awareness merely complicates the picture. For example, will they
communicate the risks and benefits of developments such as fertility
tourism or technological innovations unavailable at their own clinics to
patients? Is such information material to the project of informed consent,
wherein physicians must inform patients about a treatment procedure’s
risks, benefits, side effects, and alternatives? And how are these ethical
responsibilities affected by the fact that certain treatment options may
not be offered at a patient’s home clinic, or indeed, within the borders of
the United States? The future of fertility treatments will increasingly take
place within a global marketplace; yet, no global infrastructure exists for
determining the safety or the ethical permissibility of the developments
on the horizon.

196. Jonathan O’Callaghan, First Lab-Grown Human Sperm Technique Revealed by Scientists, IFL SCI.
(Sept. 21, 2015), http://www.iflscience.com/health-and-medicine/human-sperm-created-lab-firsttime-scientists-claim [https://perma.cc/KCD4-NSMK].

